MoCD Type A is a rare, inborn error of metabolism caused by mutations in the MOCS1 gene that results in toxic sulfite accumulation in the brain. Nulibry ...
Nulibry replaces missing cyclic pyranopterin monophosphate, which is needed to reduce levels of neurotoxic sulfites. The Food and Drug Administration (FDA) has approved Nulibry ™ (fosdenopterin) for ...
Guenter Schwarz et al, Increased Survival in Patients With Molybdenum Cofactor Deficiency Type A Treated With Cyclic Pyranopterin Monophosphate, Journal of Inherited Metabolic Disease (2025).
The disorder known as molybdenum cofactor deficiency (MoCD) Type A presents shortly after birth, often with severe encephalopathy and intractable seizures. The FDA approved the first therapy for an ...
RECENT experiments with groundnuts, Arachis hypogea, on the Muara plots near Bogor, Java, have shown that small applications of molybdenum produce a markedly beneficial effect on the colour and growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results